ARMO BioSciences, a late-stage immunotherapy 2.0 biotech targeting advanced cancers, raised $128 million by offering 7.5 million shares at $17. It originally planned to offer 6.7 million shares at a price range of $14 to $16. Insiders had indicated on up to $40 million of the deal. ARMO BioSciences plans to list on the Nasdaq under the symbol ARMO. Jefferies, Leerink Partners and BMO Capital Markets acted as lead managers on the deal.
